NASDAQ:CGIX

Cancer Genetics (CGIX) Stock Forecast, Price & News

$0.24

-0.02 (-7.84%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.21
▼
$0.24
50-Day Range: $0.21
▼
$0.65
52-Week Range: $2.11
▼
$17.50

Volume: 3,039 shs
Average Volume: 2.44 million shs
Market Capitalization: $960,383.50

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Headlines Social Media

About Cancer Genetics (NASDAQ:CGIX) Stock

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

CGIX Stock News Headlines

June 3, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Cancer Genetics (NASDAQ:CGIX)

June 2, 2023 | msn.com

Endometrial Cancer Warning Signs: What to Look Out For

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 25, 2023 | msn.com

UCLA researchers say genetic mutation could be key to treating fatal brain tumors

May 25, 2023 | americanbankingnews.com

Cancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at StockNews.com

May 18, 2023 | msn.com

Junk genes may hold keys to cancer cure, CWRU researchers find

May 17, 2023 | americanbankingnews.com

Cancer Genetics (NASDAQ:CGIX) Receives New Coverage from Analysts at StockNews.com

May 16, 2023 | technews.tmcnet.com

New Study Shows CancerIQ Plus Point-of-Care Genetic Testing Improves Access to Precision Prevention

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

May 9, 2023 | americanbankingnews.com

Cancer Genetics (NASDAQ:CGIX) Coverage Initiated by Analysts at StockNews.com

May 8, 2023 | washingtonpost.com

Ask a Doctor: Which cancers can be detected through genetic testing?

May 8, 2023 | markets.businessinsider.com

Genome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer Care

April 27, 2023 | msn.com

Calls for ban on insurance companies using genetic testing information as doctors warn it puts Kiwis at risk

April 12, 2023 | msn.com

Scientists say 'genetic clues' could lead to blood test tracking cancer growth in real time

April 3, 2023 | foxnews.com

AI testing of brain tumors can detect genetic cancer markers in less than 90 seconds, study finds

March 31, 2023 | msn.com

Canadian researchers find new gene mutation that could be linked to increased breast cancer risk

March 30, 2023 | dailymail.co.uk

Cancer

March 29, 2023 | foxnews.com

New breast cancer gene can predict likelihood of hereditary disease, study finds

March 27, 2023 | nypost.com

‘Holy grail’ of cancer detection predicts tumors a year before they form: breakthrough

March 27, 2023 | msn.com

Genetic testing: How four generations of a family have battled multiple cancers

March 25, 2023 | msn.com

Saliva: The Next Frontier In Cancer Detection

March 25, 2023 | news.yahoo.com

Hundreds call helpline over Orkney cancer gene

March 23, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Cancer Genetics (NASDAQ:CGIX)

March 13, 2023 | msn.com

San Diego Genetic Sequencing Pioneer Illumina Fends Off Carl Icahn Proxy Bid

March 5, 2023 | benzinga.com

PROSTATE CANCER FOUNDATION-FUNDED GENETIC STUDY OF MEN OF AFRICAN ANCESTRY FINDS NEW RISK FACTORS FOR PROSTATE CANCER

March 1, 2023 | usnews.com

Is Obesity Especially Dangerous for Women at Genetic Risk for Breast Cancer?

March 1, 2023 | marketwatch.com

Latest Research on Breast Cancer Liquid Biopsy Market Report 2023-2029

See More Headlines

CGIX Price History

30 days | 90 days | 365 days | Advanced Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: N/A
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CGIX
CUSIP: N/A
CIK: N/A
Web: www.cancergenetics.com
Phone: (201) 479-1357
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $6.33 million
Price / Sales: 0.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,085,000
Free Float: N/A
Market Cap: $960,383.50
Optionable: Not Optionable
Beta: 2.72

Key Executives

John A. Roberts
President, Chief Executive Officer & Director

Andrew D. C. LaFrence
Chief Operating & Financial Officer

Robert T. Fremeau
Chief Scientific Officer

Ping Yeh
Director & Chief Innovation Officer

Ralf Brandt
President-Discovery & Early Development Services

Key Competitors

View All Competitors

CGIX Stock - Frequently Asked Questions

How have CGIX shares performed in 2023?: Cancer Genetics' stock was trading at $0.7025 at the beginning of 2023. Since then, CGIX shares have decreased by 66.5% and is now trading at $0.2351.
View the best growth stocks for 2023 here.
What is Panna Sharma's approval rating as Cancer Genetics' CEO?: 28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Cancer Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD).
What is Cancer Genetics' stock symbol?: Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?: Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cancer Genetics' stock price today?: One share of CGIX stock can currently be purchased for approximately $0.24.
How much money does Cancer Genetics make?: Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $960,383.50 and generates $6.33 million in revenue each year.
How can I contact Cancer Genetics?: Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial